Skip to main content
PTSD & Trauma

rTMS Added to Cognitive Processing Therapy in Combat Veterans with PTSD

Grade A-Randomized, sham-controlled trial2018

What did this study find?

This randomized trial assigned 103 combat veterans with PTSD to active or sham repetitive TMS immediately before each weekly session of cognitive processing therapy. The active group showed significantly greater symptom reduction early in treatment, and the advantage was sustained up to six months. TMS is a clinical procedure distinct from consumer PEMF devices.

What are the details of this record?

Full citation
Kozel FA, Motes MA, Didehbani N, et al. Repetitive TMS to augment cognitive processing therapy in combat veterans of recent conflicts with PTSD: A randomized clinical trial. J Affect Disord. 2018;229:506-514. doi:10.1016/j.jad.2017.12.046.
Journal
Journal of Affective Disorders
Authors
Kozel FA, Motes MA, Didehbani N, DeLaRosa B, Bass C, Schraufnagel CD, Jones P, Morgan CR, Spence JS, Kraut MA, Hart J Jr
Study design
Randomized, sham-controlled trial
Sample size and population
103 combat veterans with PTSD (54 active rTMS, 49 sham)
Evidence grade
Grade A- on the BioReg grading scale
Reported findings
Right prefrontal 1 Hz rTMS given just before weekly cognitive processing therapy produced significantly greater PTSD symptom reduction than sham plus therapy, early in treatment and sustained up to six months. Transcranial magnetic stimulation is a clinical procedure; findings do not transfer directly to PEMF devices.

A positive PEMF study is not evidence for a specific device unless the signal parameters studied, frequency, intensity, waveform, and exposure duration, are reasonably comparable to what that device produces. Where this record does not list those parameters, the source report did not publish them. See the grading methodology. Library last reviewed 2026-08-27.